News > Hetero starts the supply of a generic version of Remdesivir, ‘Covifor’

Hetero starts the supply of a generic version of Remdesivir, ‘Covifor’

Remdesivir is the only drug approved by USFDA for Emergency Use Authorisation (EUA) treatment of patients hospitalized with COVID-19 infection. The MRP of Remdesivir is Rs. 5,400, however, it costs patients around Rs. 7,000 including other charges.

Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, a generic version of Remdesivir in India from July 13 to 20. It is meant for the treatment of COVID-19 patients, majorly adults, and children that are hospitalized with severe symptoms of the disease.